Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: Myriad is a biotechnology company focused on molecular diagnostics and drug development. Its operations are divided into three segments: Research, Molecular Diagnostics, and Drug Development. The company has not yet attained profitability and relies on equity financing and diagnostic revenues to fund operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2007 | Nine Months Ended Mar 31, 2007 | Nine Months Ended Mar 31, 2006 |
|---|---|---|---|
| Total Revenues | $40,970 | $111,648 | $82,254 |
| Net Loss | $(5,937) | $(27,158) | $(26,765) |
| Operating Loss | $(9,092) | $(35,461) | $(31,608) |
| Cash and Cash Equivalents | $194,871 | $194,871 (Balance Sheet) | $98,573 (Prior Year End) |
| Marketable Securities | $109,476 | $109,476 (Balance Sheet) | $129,171 (Prior Year End) |
| Accumulated Deficit | $(244,596) | $(244,596) | $(217,438) |
| Net Cash Used in Operating Activities | N/A | $(26,105) | $(24,739) |
Margins: Gross profit margin for the molecular diagnostics segment was 80% for the three months ended March 31, 2007, and 77% for the nine-month period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 37% year-over-year for the quarter ($40.97M vs. $29.81M) and 36% for the nine-month period ($111.65M vs. $82.25M). This was driven primarily by a 41% increase in molecular diagnostic revenue for the quarter and a 44% increase for the nine months.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 55% for the quarter and 42% for the nine months, attributed to increased headcount, marketing commissions, and costs for a direct-to-consumer advertising campaign. Research and development (R&D) expenses increased 7% for the quarter and 25% for the nine months due to expanded clinical trials.
- Liquidity Position: Cash and cash equivalents increased significantly from $98.6 million at June 30, 2006, to $194.9 million at March 31, 2007. This was primarily due to net proceeds of $105.3 million from a public offering of common stock in February 2007.
- Net Loss: While the net loss for the nine months ended March 31, 2007 ($27.2M) was slightly higher than the prior year ($26.8M), the loss per share improved to $(0.67) from $(0.76) due to the increase in weighted average shares outstanding.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and the launch of new diagnostic products. They believe existing capital resources are sufficient to fund operations for at least the next two years.
- Clinical Trials:
- Flurizan (Alzheimer's): Two Phase 3 trials are ongoing with enrollment complete (1,684 patients in the US; 840 in Europe/Canada/US).
- Azixa (Cancer): Two Phase 2 trials have begun for glioblastoma and melanoma with brain metastases.
- MPC-2130 & MPC-0920: Phase 1 trials are underway for blood cancers and thrombosis, respectively.
- Risks: Key risks include the failure of clinical trials to produce marketable products, delays in regulatory approval, the high cost of developing new drugs, and the ability to secure future financing. The company also faces risks related to patent infringement and competition.
- Unusual Items: The filing notes a significant increase in share-based compensation expense ($5.2M for the nine months) due to the adoption of SFAS 123R.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current cash position ($194.9M cash + $109.5M securities) against the projected operating losses and capital expenditures for the next 24 months.
- Clinical Trial Milestones: Monitor the progress and preliminary data release dates for the Phase 3 Flurizan trials and Phase 2 Azixa trials, as these are critical to future valuation.
- Revenue Concentration: Assess the reliance on the four core molecular diagnostic products (BRACAnalysis, COLARIS, COLARIS AP, MELARIS) and the potential impact of reimbursement changes or competition.
- Equity Dilution: Review the remaining capacity under the shelf registration statement ($43.4M available) and the potential for future equity offerings to fund operations.
- Bad Debt Provision: Note the increase in the allowance for doubtful accounts and bad debt expense ($3.8M for the nine months), which may indicate collection challenges as receivables grow.